Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.770
+0.005 (0.65%)
At close: May 1, 2024, 4:00 PM
0.750
-0.020 (-2.60%)
Pre-market: May 2, 2024, 6:45 AM EDT
Aligos Therapeutics Revenue
In the year 2023, Aligos Therapeutics had annual revenue of $15.53M with 11.66% growth. Revenue in the quarter ending December 31, 2023 was $2.68M, a -24.20% decrease year-over-year.
Revenue (ttm)
$15.53M
Revenue Growth
+11.66%
P/S Ratio
3.60
Revenue / Employee
$235,288
Employees
66
Market Cap
55.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.53M | 1.62M | 11.66% |
Dec 31, 2022 | 13.91M | 9.55M | 219.04% |
Dec 31, 2021 | 4.36M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 1.16B |
Eagle Pharmaceuticals | 257.55M |
Bionano Genomics | 36.12M |
Prenetics Global | 21.74M |
HCW Biologics | 560.36K |
ALGS News
- 1 day ago - Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 6 days ago - Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study - GlobeNewsWire
- 5 weeks ago - Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 - GlobeNewsWire
- 5 months ago - Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) - GlobeNewsWire